It appears FDA’s generic drug application backlog did the exact opposite of what the agency hoped when it asked sponsors to voluntarily withdraw inactive or unnecessary submissions.
Rather than decrease or plateau from the 2,500 submissions that were pending at the end of fiscal year 2011, the backlog increased more than 16% to 2,911 as of Sept....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?